Novavax (NVAX) Accumulated Expenses (2010 - 2026)
Novavax's Accumulated Expenses came in at $81.42 million for Q2 2026, down 6.1% from $86.7 million a year earlier and down 21.0% from the prior quarter.
Powered by 
Analysis
Novavax (NVAX) Accumulated Expenses (2010 - 2026) Analysis & Trends
At the end of FY2025, Novavax's Accumulated Expenses was $107.17 million, down 49.3% from FY2024.
- Accumulated Expenses has declined in each of the last four years, with a five-year compound annual growth rate of -4.8% (FY2020 to FY2025).
- Going back by year, Accumulated Expenses was $211.17 million in FY2024 (-46.5%), $394.67 million in FY2023 (-33.2%), $591.16 million in FY2022 (-12.3%) and $673.73 million in FY2021 (+390.4%).
- The Q2 2026 figure represents the lowest quarterly Accumulated Expenses since Q3 2020.
- Year-over-year, Accumulated Expenses has declined for 15 consecutive quarters, with an average decline of 36.9% over the last eight quarters.
- The fastest year-over-year change in Accumulated Expenses over five years came in Q4 2021 (growth of 390.4%), and the weakest in Q2 2024 (a decline of 65.3%).
- Business Quant data shows NVAX's Accumulated Expenses at $103.03 million (Q1 2026), $107.17 million (Q4 2025) and $115.59 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,261.99 Bn | 1,235.61 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 678.93 Bn | 598.79 Bn | 17.30 Bn |
| 3 | AbbVie | 518.29 Bn | 486.30 Bn | 13.12 Bn |
| 4 | Merck | 365.98 Bn | 328.92 Bn | 13.19 Bn |
| 5 | Novartis Ag | 316.85 Bn | 290.09 Bn | - |
| 6 | Astrazeneca | 293.40 Bn | 267.29 Bn | 13.26 Bn |
| 7 | Amgen | 251.78 Bn | 203.43 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 210.61 Bn | 185.71 Bn | 6.73 Bn |
| 9 | Pfizer | 166.87 Bn | 114.23 Bn | 12.56 Bn |
| 10 | Novavax | 1.80 Bn | -1.06 Bn | 44.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 77.40 Mn |
| Jun 30, 2026 | 81.42 Mn |
| Mar 31, 2026 | 103.03 Mn |
| Dec 31, 2025 | 107.17 Mn |
| Sep 30, 2025 | 115.59 Mn |
| Jun 30, 2025 | 86.70 Mn |
| Mar 31, 2025 | 132.17 Mn |
| Dec 31, 2024 | 211.17 Mn |
| Sep 30, 2024 | 218.67 Mn |
| Jun 30, 2024 | 159.22 Mn |
| Mar 31, 2024 | 257.37 Mn |
| Dec 31, 2023 | 394.67 Mn |
| Sep 30, 2023 | 311.20 Mn |
| Jun 30, 2023 | 458.40 Mn |
| Mar 31, 2023 | 518.71 Mn |
| Dec 31, 2022 | 591.16 Mn |
| Sep 30, 2022 | 551.07 Mn |
| Jun 30, 2022 | 585.65 Mn |
| Mar 31, 2022 | 559.88 Mn |
| Dec 31, 2021 | 673.73 Mn |
API Access
Novavax Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=NVAX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "accumulated-expenses", "ticker": "NVAX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=NVAX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();